173 related articles for article (PubMed ID: 30365110)
1. Peptides and small molecules blocking the CXCR4/CXCL12 axis overcome bone marrow‑induced chemoresistance in acute leukemias.
Pillozzi S; Bernini A; Spiga O; Lelli B; Petroni G; Bracci L; Niccolai N; Arcangeli A
Oncol Rep; 2019 Jan; 41(1):312-324. PubMed ID: 30365110
[TBL] [Abstract][Full Text] [Related]
2. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
[TBL] [Abstract][Full Text] [Related]
3. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
Tabe Y; Shi YX; Zeng Z; Jin L; Shikami M; Hatanaka Y; Miida T; Hsu FJ; Andreeff M; Konopleva M
PLoS One; 2013; 8(6):e62785. PubMed ID: 23826077
[TBL] [Abstract][Full Text] [Related]
4. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells.
Hartmann TN; Burger JA; Glodek A; Fujii N; Burger M
Oncogene; 2005 Jun; 24(27):4462-71. PubMed ID: 15806155
[TBL] [Abstract][Full Text] [Related]
5. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis.
Li X; Guo H; Duan H; Yang Y; Meng J; Liu J; Wang C; Xu H
Sci Rep; 2015 Nov; 5():16228. PubMed ID: 26538086
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.
Zeng Z; Samudio IJ; Munsell M; An J; Huang Z; Estey E; Andreeff M; Konopleva M
Mol Cancer Ther; 2006 Dec; 5(12):3113-21. PubMed ID: 17172414
[TBL] [Abstract][Full Text] [Related]
7. CXCR4-mediated signaling regulates autophagy and influences acute myeloid leukemia cell survival and drug resistance.
Hu X; Mei S; Meng W; Xue S; Jiang L; Yang Y; Hui L; Chen Y; Guan MX
Cancer Lett; 2018 Jul; 425():1-12. PubMed ID: 29574276
[TBL] [Abstract][Full Text] [Related]
8. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
[TBL] [Abstract][Full Text] [Related]
10. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?
Tavor S; Petit I
Semin Cancer Biol; 2010 Jun; 20(3):178-85. PubMed ID: 20637871
[TBL] [Abstract][Full Text] [Related]
11. CXCL12/CXCR4 axis induced miR-125b promotes invasion and confers 5-fluorouracil resistance through enhancing autophagy in colorectal cancer.
Yu X; Shi W; Zhang Y; Wang X; Sun S; Song Z; Liu M; Zeng Q; Cui S; Qu X
Sci Rep; 2017 Feb; 7():42226. PubMed ID: 28176874
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers.
Pillozzi S; Masselli M; De Lorenzo E; Accordi B; Cilia E; Crociani O; Amedei A; Veltroni M; D'Amico M; Basso G; Becchetti A; Campana D; Arcangeli A
Blood; 2011 Jan; 117(3):902-14. PubMed ID: 21048156
[TBL] [Abstract][Full Text] [Related]
13. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia.
Landry B; Gül-Uludağ H; Plianwong S; Kucharski C; Zak Z; Parmar MB; Kutsch O; Jiang H; Brandwein J; Uludağ H
J Control Release; 2016 Feb; 224():8-21. PubMed ID: 26742943
[TBL] [Abstract][Full Text] [Related]
14. The bone marrow microenvironment and leukemia: biology and therapeutic targeting.
Sison EA; Brown P
Expert Rev Hematol; 2011 Jun; 4(3):271-83. PubMed ID: 21668393
[TBL] [Abstract][Full Text] [Related]
15. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
Sison EA; Magoon D; Li L; Annesley CE; Rau RE; Small D; Brown P
Oncotarget; 2014 Oct; 5(19):8947-58. PubMed ID: 25333254
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance.
Jonart LM; Ostergaard J; Brooks A; Fitzpatrick G; Chen L; Gordon PM
Br J Haematol; 2023 May; 201(3):459-469. PubMed ID: 36535585
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of the interactions between CXCR4 and CXCL12/SDF-1 revealed by theoretical approaches.
Xu L; Li Y; Sun H; Li D; Hou T
Mol Biosyst; 2013 Aug; 9(8):2107-17. PubMed ID: 23702796
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways.
Scupoli MT; Donadelli M; Cioffi F; Rossi M; Perbellini O; Malpeli G; Corbioli S; Vinante F; Krampera M; Palmieri M; Scarpa A; Ariola C; Foà R; Pizzolo G
Haematologica; 2008 Apr; 93(4):524-32. PubMed ID: 18322253
[TBL] [Abstract][Full Text] [Related]
19. Interaction of chemokine receptor CXCR4 in monomeric and dimeric state with its endogenous ligand CXCL12: coarse-grained simulations identify differences.
Cutolo P; Basdevant N; Bernadat G; Bachelerie F; Ha-Duong T
J Biomol Struct Dyn; 2017 Feb; 35(2):399-412. PubMed ID: 26813575
[TBL] [Abstract][Full Text] [Related]
20. Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia.
van den Berk LC; van der Veer A; Willemse ME; Theeuwes MJ; Luijendijk MW; Tong WH; van der Sluis IM; Pieters R; den Boer ML
Br J Haematol; 2014 Jul; 166(2):240-9. PubMed ID: 24697337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
